NIH Directors Transformative Research Awards (R01 Clinical Trial Optional)
ID: 353035Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/353035

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-RM-24-004.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Directors Transformative Research Awards (R01 Clinical Trial Optional) to support innovative and groundbreaking research that has the potential to significantly advance scientific paradigms and improve health outcomes. This funding opportunity encourages applications from individual scientists or collaborative teams, particularly those from diverse and underrepresented backgrounds, without the requirement for preliminary data, provided they can demonstrate a compelling rationale for their proposed research. The NIH aims to minimize barriers to high-risk, high-reward research, with approximately $8 million available for around seven awards, each with a maximum project period of five years. Interested applicants must submit their proposals by September 4, 2024, and can find additional information and submission guidelines at the NIH grants website or contact grantsinfo@nih.gov for inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-RM-24-004-Full-Announcement.html
    RFA-RM-24-004.html
    The NIH Director's Transformative Research Awards (R01 Clinical Trial Optional) funding opportunity aims to support innovative research that has the potential to create groundbreaking scientific advancements. This initiative encourages individual scientists or collaborative teams from diverse backgrounds to pursue research that may transform traditional paradigms or lead to significant health improvements. Applicants do not need preliminary data but must demonstrate a compelling logic to justify their proposed research. The funding opportunity will provide approximately $8 million in FY 2025 for around seven awards, with a maximum project period of five years. Key application aspects include strict anonymization protocols during peer review to ensure impartial evaluations and a focus on the significance and innovation of proposed projects. Additionally, the NIH emphasizes the importance of diversity in the research workforce, inviting applications from institutions serving underrepresented communities. Applications must comply with specific submission guidelines and are due by September 4, 2024. Overall, this initiative seeks to minimize barriers to high-risk, high-reward research to foster transformative scientific progress across various health-related fields.
    Similar Opportunities
    NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R21 Clinical Trial Optional mechanism, aimed at supporting exploratory and developmental research in cancer diagnosis, treatment, imaging, symptom management, and prevention. This grant is designed to encourage innovative studies that challenge existing paradigms and address critical barriers in cancer research, particularly focusing on reducing disparities among underserved populations. Eligible applicants include a wide range of organizations, such as historically black colleges, tribal governments, and faith-based organizations, with a maximum funding amount of $275,000 available over a two-year period. Interested parties can find more information and application details at the provided link, with a submission deadline of July 1, 2025, and inquiries directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required) to support innovative research projects at the preliminary or conceptual stage, particularly those with the potential to advance biomedical, behavioral, or clinical research. Applicants must include at least one clinical trial in their proposals, focusing on mechanistic studies that align with the scientific missions of participating NIH Institutes and Centers. This funding opportunity is crucial for stimulating novel research that challenges conventional methods and improves clinical practices, with a maximum budget of $275,000 available for a two-year project, and no more than $200,000 allocated in any single year. Interested applicants should adhere to strict submission guidelines and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for assistance; the application deadline is January 7, 2025.
    NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIMHD Exploratory/Developmental Research Grant Program (R21 - Clinical Trial Optional) to support innovative research aimed at addressing minority health and health disparities in the United States. This grant invites applications for short-term exploratory projects that can either pioneer new advancements or build upon previous findings, with a maximum funding amount of $275,000 available for a two-year project period, limiting annual requests to $200,000. The program emphasizes the importance of diverse representation among applicants and encourages partnerships with relevant stakeholders, focusing on NIH-designated health disparity populations through various research methodologies. Interested applicants can find more information and submission guidelines at the provided link, with the application deadline set for May 7, 2026. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Trailblazer Award for New and Early Stage Investigators through the R21 Clinical Trial Optional grant mechanism, aimed at fostering innovative research that integrates engineering and physical sciences with biomedical sciences. This funding opportunity encourages exploratory, proof of concept, or high-risk projects, specifically those that do not require extensive preliminary data, allowing applicants to propose novel research approaches. Eligible applicants include a diverse range of institutions and organizations, with funding of up to $400,000 available over a maximum of three years. Interested parties should submit their applications electronically via Grants.gov by the close date of January 7, 2026, and can direct inquiries to grantsinfo@nih.gov for further information.
    Research Project Grant (Parent R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Research Project Grant (Parent R01 Clinical Trial Required) to support specified clinical research projects that align with the missions of various NIH institutes. Applicants are required to propose at least one clinical trial, focusing on significant health-related research areas, and must comply with the NIH Grants Policy Statement. This funding opportunity is crucial for advancing medical science and improving patient care, emphasizing innovation and scientific merit in addressing important health issues. The application deadline is January 7, 2025, and interested parties can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further inquiries. More details can be found at the provided link: http://grants.nih.gov/grants/guide/pa-files/PA-20-183.html.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) to support innovative biomedical and clinical research projects. This grant aims to foster exploratory research that may involve significant risks but has the potential for breakthroughs or the development of novel methodologies in health-related fields. The program is crucial for advancing research that addresses pressing health challenges and encourages applications that present new scientific ideas distinct from traditional R01 projects. Eligible applicants include a wide range of institutions, including higher education institutions, nonprofits, and for-profit organizations, both domestic and foreign, with a budget limit of $275,000 over two years and a maximum request of $200,000 in any single year. Interested parties should submit their applications electronically by January 7, 2025, and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further assistance.
    Research Opportunities for New and "At-Risk" Investigators to Promote Workforce Diversity (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Opportunities for New and 'At-Risk' Investigators to Promote Workforce Diversity" (PAR-22-181), aimed at enhancing the diversity of the biomedical research workforce. This initiative invites R01 grant applications for independent research projects that align with the scientific missions of participating NIH Institutes or Centers, specifically targeting New Investigators and At-Risk Investigators from underrepresented backgrounds, including racial and ethnic minorities and individuals with disabilities. The program emphasizes the importance of addressing health disparities and promoting diverse representation in science, with funding allocations of up to $10 million for NINDS and $5 million for NIDA/NIMH, among others, for a maximum project period of five years. Interested applicants should submit their proposals by June 6, 2025, and can direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further information.
    NCI Outstanding Investigator Award (R35 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NCI Outstanding Investigator Award (R35), aimed at providing long-term support for exceptional cancer research projects. This grant opportunity is designed for accomplished investigators with a proven track record in cancer research, allowing them to pursue innovative and high-risk projects that could lead to significant advancements in the field. The award offers up to $600,000 in direct costs per year for a maximum duration of seven years, with applications due by November 7, 2024. Interested applicants can find more information and contact details at the provided link: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-22-045.html.
    Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)," aimed at supporting studies that address barriers to the adoption and sustainability of evidence-based health interventions, particularly in underserved communities. The initiative encourages research that promotes equitable access to effective practices and explores methods for discontinuing ineffective or harmful interventions, emphasizing the importance of contextual factors and multidisciplinary collaboration. Eligible applicants include a wide range of organizations such as higher education institutions, nonprofits, and tribal governments, with a maximum funding amount of $275,000 and a project period of up to two years. Interested parties can find more information and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by May 7, 2025.
    Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Investigator Initiated Extended Clinical Trial (R01 Clinical Trial Required), inviting applications for long-term clinical trials lasting 6 or 7 years. These trials must be hypothesis-driven, aligned with NIH's research mission, and include clearly defined objectives and milestone planning to monitor progress. This initiative emphasizes the importance of extended clinical trials in advancing critical biomedical research, with no specific budget limits but requiring justification based on project needs. Interested applicants must consult with NIH staff prior to submission, adhere to new application forms and data sharing policies, and submit their applications by January 13, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-084.html.